Otonomy's Meniere’s disease candidate meets in Phase III

Otonomy Inc. (NASDAQ:OTIC) reported top-line data from the double-blind, European Phase III AVERTS-2 trial in 174 patients with unilateral Meniere’s disease showing that a single 12 mg intratympanic

Read the full 287 word article

User Sign In